Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GLUCOPHAGE Bristol-Myers Squibb · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC |
| 2 | EXPERIMENTAL | Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC |
| 3 | ACTIVE_COMPARATOR | GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb |
| 4 | ACTIVE_COMPARATOR | GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb |
| Name | Type | Description |
|---|---|---|
| Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC | DRUG | - |
| GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |